Quest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.
- Revenue
- +9.98%
- EPS
- +29.4%
- Free cash flow
- +6.21%
- Total debt
- −2.20%
Quarter to September 2026, against a year earlier
Follow DGX
Alert me
Quest Diagnostics Incorporated (DGX) P/S ratio
As of 5 November 2026, Quest Diagnostics Incorporated (DGX) trades at a P/S ratio of 2.4×. Over the past ten years it has ranged from 1.2× (September 2015) to 2.4× (September 2026); the current reading is higher than 100% of that period. That is below the Diagnostics & Research industry median of 4.2× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 1.7× | 2.90% |
| FY2024 | 1.7× | (0.49%) |
| FY2023 | 1.7× | (6.76%) |
| FY2022 | 1.8× | (8.80%) |
| FY2021 | 2.0× | 18.47% |
| FY2020 | 1.7× | (8.64%) |
| FY2019 | 1.9× | 23.18% |
| FY2018 | 1.5× | (17.85%) |
| FY2017 | 1.8× | 2.02% |
| FY2016 | 1.8× | 31.23% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 2.2× | 6.39% |
| Jun 2026 | 2.0× | 6.47% |
| Mar 2026 | 1.9× | 9.51% |
| Dec 2025 | 1.7× | (11.27%) |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| LH Labcorp Holdings Inc. compare | 2.0× |
| DGX Quest Diagnostics Incorporated | 2.4× |
| IQV IQVIA Holdings Inc. compare | 2.5× |
| RVTY Revvity Inc. compare | 5.7× |
| MEDP Medpace Holdings, Inc. compare | 6.2× |
| ILMN Illumina, Inc. compare | 7.0× |
| WAT Waters Corporation compare | 8.0× |
| MTD Mettler-Toledo International, Inc. compare | 8.2× |
| GH Guardant Health, Inc. compare | 16.2× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on DGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement